Board Growth Amulet has actively expanded its governance with multiple recent board appointments including Darcey Nett, Lisa Strovink, and Katie Brenner, signaling a strategic emphasis on governance, fundraising credibility, and commercial partnerships that can open doors for enterprise collaborations and strategic investors.

Funding Momentum The company secured a $6M Series A in 2024 and maintains total funding of $14M, indicating strong investor confidence and available growth capital to support large-scale manufacturing integrations, regulatory approvals, or customer-centric product deployments.

Enterprise Focus Amulet serves both consumer safety via Allergy Amulet and industry applications via Amulet Scientific, presenting parallel sales avenues to food manufacturers, testing labs, and食品service platforms seeking toxin and contaminant targeting capabilities.

Public-Research Backing Past funding and support from NIH and USDA underscore credibility in biotech research and potential for grant-aligned collaborations, offering co-selling opportunities with government-funded programs and access to research-enabled customer pilots.

Tech and Growth Fit A tech-enabled go-to-market, utilizing platforms such as Salesforce, HubSpot, Squarespace, and Google Workspace, suggests readiness for scalable sales outreach, CRM-driven account targeting, and digital marketing to reach mid-market and strategic enterprise customers.